Grail, Inc. GRAL

What this company does

GRAIL, Inc. offers Galleri, a multi-cancer early detection test that can screen for many types of cancer and predict the specific organ or tissue type where a cancer signal originated, from a blood draw. Galleri is offered as a laboratory-developed test through the company's CAP-accredited, CLIA-certified laboratory. As of December 31, 2025, the company had approximately 910 full-time employees. The company's headquarters are in Menlo Park, California, with operations in Durham, North Carolina, Washington, D.C., and London, United Kingdom. On June 24, 2024, GRAIL, LLC was converted into a Delaware corporation and renamed GRAIL, Inc. as part of a spin-off in which Illumina distributed 85.5% of GRAIL's common stock to Illumina's stockholders, and GRAIL became an independent, publicly traded company.

Written from the business description in GRAIL, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.